Detected ·
Claris Bio
$118M—
Claris Bio, a New Jersey-based clinical-stage biotech, raised $118M in a Series B round co-led by Samsara BioCapital and Catalio Capital Management to advance CSB-001, a potential first-in-class eye drop for limbal stem cell deficiency.
- Website
- —
- —
- Amount
- $118 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-29 00:01:56 UTC
- Signal ID
- 4db318af-e707-4666-a84a-53c6d5ce4b28
As the API returns it
{
"id": "4db318af-e707-4666-a84a-53c6d5ce4b28",
"created_at": "2026-07-29T00:01:56.945681Z",
"company_name": "Claris Bio",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 118000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Claris Bio, a New Jersey-based clinical-stage biotech, raised $118M in a Series B round co-led by Samsara BioCapital and Catalio Capital Management to advance CSB-001, a potential first-in-class eye drop for limbal stem cell deficiency.*"
}